Cargando…
Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?
INTRODUCTION: Past trials of buprenorphine (BUP) in the treatment of major depressive disorder (MDD) have displayed favorable results, although its clinical utility was limited by the risk of abuse or physical dependence. By combining BUP with samidorphan (SAM), the euphoric high is negated by an op...
Autores principales: | Peckham, Alyssa M., De La Cruz, Austin, Dufresne, Robert L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
College of Psychiatric & Neurologic Pharmacists
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063454/ https://www.ncbi.nlm.nih.gov/pubmed/30155392 http://dx.doi.org/10.9740/mhc.2018.07.175 |
Ejemplares similares
-
Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review
por: Laguado, S. Andrea, et al.
Publicado: (2022) -
Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
por: Diefenderfer, Lauren A., et al.
Publicado: (2018) -
Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action
por: Irwin, Madison N., et al.
Publicado: (2021) -
Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy
por: Camarero, Tamara García, et al.
Publicado: (2020) -
Role of antidepressants in the treatment of adults with anorexia nervosa
por: Marvanova, Marketa, et al.
Publicado: (2018)